Major Milestone Reached in the SirPAD Trial
Concept Medical Inc. proudly announces the successful completion of patient enrollment in the SirPAD Trial, enrolling over 1,250 patients. This trial focuses on the MagicTouch PTA Sirolimus Coated Balloon, a revolutionary approach to treating Peripheral Artery Disease (PAD).
Understanding the SirPAD Trial
The SirPAD trial stands out as the largest randomized controlled study testing the effectiveness of sirolimus-coated balloons for treating PAD. This innovative trial compares the treatment efficacy of the MagicTouch PTA sirolimus-coated balloon against traditional uncoated balloons.
Enrollment and Follow-Up
With more than 1,250 patients participating, the trial is set to conduct a follow-up at the 12-month mark to evaluate the primary outcome: major adverse limb events (MALE). The final results are anticipated to provide invaluable insights into the treatment options for PAD in Q1-Q2 2026.
Trial Objectives and Design
As an investigator-initiated, multi-center, randomized, open-label trial, SirPAD aims to ascertain whether the sirolimus-coated balloon demonstrates non-inferiority when compared to plain old balloon angioplasty (POBA). Moreover, the trial seeks to explore the potential for superior outcomes.
Quotes from Leading Investigators
Principal investigators, Prof. Dr. med. Nils Kucher and Prof. Dr. med. Stefano Barco from a distinguished university hospital, expressed their excitement about reaching this significant milestone. They emphasized the importance of randomized trials in providing solid evidence to inform treatment decisions and improve clinical outcomes for PAD patients.
Importance of Sirolimus-Coated Balloons
As the momentum behind sirolimus-coated balloons continues to grow, the SirPAD study represents an essential step forward in validating this promising technology. Patients suffering from PAD often have limited treatment options, making this trial vital for expanding therapeutic avenues and solidifying support for sirolimus-coated balloons.
Commitment to Evidence-Based Medicine
Concept Medical is dedicated to creating robust clinical evidence to back its innovative technologies. The recent enrollment completion in the SirPAD trial follows the successful SIRONA trial, which compared its devices against paclitaxel drug-coated balloons. These milestones showcase Concept Medical's commitment to leading research and emphasizing patient-centric solutions in vascular interventions.
About Concept Medical Inc.
Headquartered in Tampa, Florida, Concept Medical Inc. is a pioneering company in drug-delivery technologies for vascular interventions. With proprietary platforms, the company is dedicated to improving patient outcomes through precision delivery of pharmaceutical agents across vascular surfaces. Their flagship MagicTouch family of Sirolimus Coated Balloons has revolutionized treatment for both coronary and peripheral artery diseases, with over a million successful interventions performed worldwide.
Frequently Asked Questions
What is the SirPAD trial?
The SirPAD trial is the largest randomised controlled trial investigating the effectiveness of the MagicTouch PTA sirolimus-coated balloon for treating Peripheral Artery Disease (PAD).
How many patients were enrolled in the trial?
More than 1,250 patients have enrolled in the SirPAD trial, making it the largest study of its kind.
What are the expected outcomes of the trial?
The primary outcome being evaluated is the incidence of major adverse limb events (MALE) at the 12-month follow-up.
What is the significance of sirolimus-coated balloons?
Sirolimus-coated balloons represent a novel treatment option for PAD, potentially offering improved outcomes over traditional uncoated balloons.
Who leads the SirPAD trial?
The trial is led by distinguished principal investigators, Prof. Dr. med. Nils Kucher and Prof. Dr. med. Stefano Barco.
